Basilea Pharmaceutic (BPMUF) 111.0000 $BPMUF
Dotmatics Announce Speaker Line-up for User Group Meeting 2014
PR Newswire Europe - Wed Jul 23, 8:59AM CDT
BISHOPS STORTFORD, England, July 23, 2014 /PRNewswire/ --
Basilea to introduce the antibiotic ceftobiprole medocaril in Europe through Quintiles
M2 - Mon Jul 21, 7:59AM CDT
Pharmaceutical products company Basilea Pharmaceutica (Munich
K5.MU) Monday announced an agreement for the commercialisation of Zevtera/Mabelio (ceftobiprole medocaril) in Europe through Quintiles (NYSE:Q).
Basilea to launch Zevtera(r)/Mabelio(r) (ceftobiprole medocaril) in Europe through a commercial services provider
GlobeNewswire - Mon Jul 21, 12:23AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) reports that it has entered into an agreement with Quintiles (NYSE: Q) for the commercialization of Zevtera(R)/Mabelio(R) (ceftobiprole medocaril) in Europe.
Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections
Thomson Reuters ONE - Thu Jul 17, 1:46AM CDT
Basilea Pharmaceutica AG / Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis
Thomson Reuters ONE - Thu Jul 17, 1:45AM CDT
Basilea Pharmaceutica AG / Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea reports that isavuconazole receives orphan drug designations in Europe for the treatment of invasive mold infections
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that the European Commission granted isavuconazole orphan drug designations for the treatment of invasive aspergillosis and mucormycosis (zygomycosis). Isavuconazole is an investigational intravenous and oral broad-spectrum antifungal.
Basilea's partner Astellas submits isavuconazole U.S. NDA for the treatment of invasive aspergillosis and invasive mucormycosis
Thomson Reuters ONE - Wed Jul 09, 10:32PM CDT
Basilea Pharmaceutica AG / Basilea's partner Astellas submits isavuconazole U.S. NDA for the treatment of invasive aspergillosis and invasive mucormycosis . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea announces start of phase 2a study with oncology drug candidate BAL101553
Thomson Reuters ONE - Thu Jun 26, 9:46PM CDT
Basilea Pharmaceutica AG / Basilea announces start of phase 2a study with oncology drug candidate BAL101553 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea provides update on ceftobiprole's U.S. regulatory status
Thomson Reuters ONE - Thu Jun 26, 9:45PM CDT
Basilea Pharmaceutica AG / Basilea provides update on ceftobiprole's U.S. regulatory status . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea initiates phase 1 combination study with its Gram-negative antibiotic BAL30072 and meropenem
GlobeNewswire - Thu Jun 12, 12:22AM CDT
-- Development program conducted under BARDA agreement
Basilea's oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study
GlobeNewswire - Mon Jun 02, 12:25AM CDT
-- Results of recently completed clinical phase 1 study presented at ASCO
Dotmatics Announce Speaker Line-up for User Group Meeting 2014
PR Newswire Europe - Wed Jul 23, 8:59AM CDT
BISHOPS STORTFORD, England, July 23, 2014 /PRNewswire/ --
Basilea to introduce the antibiotic ceftobiprole medocaril in Europe through Quintiles
M2 - Mon Jul 21, 7:59AM CDT
Pharmaceutical products company Basilea Pharmaceutica (Munich
K5.MU) Monday announced an agreement for the commercialisation of Zevtera/Mabelio (ceftobiprole medocaril) in Europe through Quintiles (NYSE:Q). Basilea to launch Zevtera(r)/Mabelio(r) (ceftobiprole medocaril) in Europe through a commercial services provider
GlobeNewswire - Mon Jul 21, 12:23AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) reports that it has entered into an agreement with Quintiles (NYSE: Q) for the commercialization of Zevtera(R)/Mabelio(R) (ceftobiprole medocaril) in Europe.
Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections
Thomson Reuters ONE - Thu Jul 17, 1:46AM CDT
Basilea Pharmaceutica AG / Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis
Thomson Reuters ONE - Thu Jul 17, 1:45AM CDT
Basilea Pharmaceutica AG / Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea reports that isavuconazole receives orphan drug designations in Europe for the treatment of invasive mold infections
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that the European Commission granted isavuconazole orphan drug designations for the treatment of invasive aspergillosis and mucormycosis (zygomycosis). Isavuconazole is an investigational intravenous and oral broad-spectrum antifungal.
Basilea's partner Astellas submits isavuconazole U.S. NDA for the treatment of invasive aspergillosis and invasive mucormycosis
Thomson Reuters ONE - Wed Jul 09, 10:32PM CDT
Basilea Pharmaceutica AG / Basilea's partner Astellas submits isavuconazole U.S. NDA for the treatment of invasive aspergillosis and invasive mucormycosis . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea announces start of phase 2a study with oncology drug candidate BAL101553
Thomson Reuters ONE - Thu Jun 26, 9:46PM CDT
Basilea Pharmaceutica AG / Basilea announces start of phase 2a study with oncology drug candidate BAL101553 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea provides update on ceftobiprole's U.S. regulatory status
Thomson Reuters ONE - Thu Jun 26, 9:45PM CDT
Basilea Pharmaceutica AG / Basilea provides update on ceftobiprole's U.S. regulatory status . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea initiates phase 1 combination study with its Gram-negative antibiotic BAL30072 and meropenem
GlobeNewswire - Thu Jun 12, 12:22AM CDT
-- Development program conducted under BARDA agreement
Basilea's oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study
GlobeNewswire - Mon Jun 02, 12:25AM CDT
-- Results of recently completed clinical phase 1 study presented at ASCO
